FDA Approves Eli Lilly's Alzheimer's Drug, Slowing the Progression of the Brain-Wasting Disease

The FDA approved Eli Lilly's Alzheimer's drug, expanding treatment options for the disease in the US. It will be sold under the brand name Kisunla. The drug targets plaques in the brain which are a hallmark of Alzheimer's disease. It has been shown to slow disease progression by 35% over 18 months compared to a placebo. The cost will range from $12,000 to $48,000. Medicare coverage is available for eligible patients. An estimated 7 million Americans currently have Alzheimer's disease, which is expected to rise to 13 million by 2050.